MDK and astrocytoma (excluding glioblastoma): In gliomas, studies of midkine (MDK) started in 1997 when Mishima et al. showed that MDK mRNA and protein expression levels were higher in high-grade astrocytomas, e.g., anaplastic astrocytomas and glioblastomas, compared to low-grade astrocytomas and healthy brain29.